Sign inCreate account

Report workspace tools

NCT04620954UNKNOWNanonymous

A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients With Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Sponsor

Source record

National Cancer Centre, Singapore

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Oregovomab, Nivolumab, Chemotherapy

Indication / condition

AI-normalized

Epithelial Ovarian Cancer

Intervention

Source record

Oregovomab, Nivolumab, Chemotherapy

Source & freshness

Source record

NCT ID

NCT04620954

Original source

ClinicalTrials.gov

Source last updated

Dec 01, 2021

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04620954

Title

A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients With Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Sponsor

National Cancer Centre, Singapore

Status

UNKNOWN

Phase

PHASE1

Condition raw

Epithelial Ovarian Cancer

Condition normalized

Epithelial Ovarian Cancer

Modality raw

ovarian cancer

Modality normalized

monoclonal antibody

Target raw

Oregovomab, Nivolumab, Chemotherapy

Target normalized

Oregovomab, Nivolumab, Chemotherapy

Interventions

Oregovomab, Nivolumab, Chemotherapy

Public preview

Source record

A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients With Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin is a PHASE1 clinical asset sponsored by National Cancer Centre, Singapore in Epithelial Ovarian Cancer. SEO and diligence focus: Oregovomab, Nivolumab, Chemotherapy, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients With Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04620954

Status

UNKNOWN

Phase

PHASE1

Sponsor

National Cancer Centre, Singapore

Executive brief

Investment-Ready Snapshot

A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients With Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin is a PHASE1 clinical asset sponsored by National Cancer Centre, Singapore in Epithelial Ovarian Cancer. SEO and diligence focus: Oregovomab, Nivolumab, Chemotherapy, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 01, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04620954

Indication

Epithelial Ovarian Cancer

Modality

monoclonal antibody

Target

Oregovomab, Nivolumab, Chemotherapy

Intervention

Oregovomab, Nivolumab, Chemotherapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.